This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

R. O. JOHNSON; W. H. WOLBERG; A. R. CURRERI

AMA Arch Surg. 1962;85(1):81-84.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

The recent interest in chemotherapy as an adjuvant to surgery has been stimulated by the slow improvement in the cure rate of human cancer,¹ animal and human studies regarding the spread of tumors,^2,3 and the observation that small areas of tumor respond better to chemotherapy than large masses of tumor.⁴ Cooperative clinical studies in the use of TSPA as an adjuvant to radical mastectomy for carcinoma of the breast have apparently shown evidence of a decreased recurrence rate in patients receiving TSPA on the day of surgery and the first and second postoperative days.⁵

In the opinion of many investigators, further improvement in chemotherapy as an adjuvant to surgery awaits the development of better anticancer agents. The fluoropyrimidines FU and FUDR have been extensively studied at this institution^6,7 and as a logical extension of these studies the feasibility of FU and FUDR as adjuvants . . . [Full Text PDF of this Article]

Author Affiliations
MADISON, WIS.

Department of Surgery, Cancer Research Hospital, University of Wisconsin Medical School.

Footnotes
This work was supported by National Institutes of Health Grant No. CY 3859.

Read at the 69th Annual Session of the Western Surgical Association, San Francisco, Nov. 29, 1961.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?